Researcher profile

Sanghamitra Bandyopadhyay

Sanghamitra Bandyopadhyay contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 13 - UnverifiedVerification L1Unclaimed author
2works
0followers
2topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2021arXiv

Decomposition in Decision and Objective Space for Multi-Modal Multi-Objective Optimization

Multi-modal multi-objective optimization problems (MMMOPs) have multiple subsets within the Pareto-optimal Set, each independently mapping to the same Pareto-Front. Prevalent multi-objective evolutionary algorithms are not purely designed to search for multiple solution subsets, whereas, algorithms designed for MMMOPs demonstrate degraded performance in the objective space. This motivates the design of better algorithms for addressing MMMOPs. The present work identifies the crowding illusion problem originating from using crowding distance globally over the entire decision space. Subsequently, an evolutionary framework, called graph Laplacian based Optimization using Reference vector assisted Decomposition (LORD), is proposed, which uses decomposition in both objective and decision space for dealing with MMMOPs. Its filtering step is further extended to present LORD-II algorithm, which demonstrates its dynamics on multi-modal many-objective problems. The efficacies of the frameworks are established by comparing their performance on test instances from the CEC 2019 multi-modal multi-objective test suite and polygon problems with the state-of-the-art algorithms for MMMOPs and other multi- and many-objective evolutionary algorithms. The manuscript is concluded by mentioning the limitations of the proposed frameworks and future directions to design still better algorithms for MMMOPs. The source code is available at https://worksupplements.droppages.com/lord.

preprint2020arXiv

Predicting potential drug targets and repurposable drugs for COVID-19 via a deep generative model for graphs

Coronavirus Disease 2019 (COVID-19) has been creating a worldwide pandemic situation. Repurposing drugs, already shown to be free of harmful side effects, for the treatment of COVID-19 patients is an important option in launching novel therapeutic strategies. Therefore, reliable molecule interaction data are a crucial basis, where drug-/protein-protein interaction networks establish invaluable, year-long carefully curated data resources. However, these resources have not yet been systematically exploited using high-performance artificial intelligence approaches. Here, we combine three networks, two of which are year-long curated, and one of which, on SARS-CoV-2-human host-virus protein interactions, was published only most recently (30th of April 2020), raising a novel network that puts drugs, human and virus proteins into mutual context. We apply Variational Graph AutoEncoders (VGAEs), representing most advanced deep learning based methodology for the analysis of data that are subject to network constraints. Reliable simulations confirm that we operate at utmost accuracy in terms of predicting missing links. We then predict hitherto unknown links between drugs and human proteins against which virus proteins preferably bind. The corresponding therapeutic agents present splendid starting points for exploring novel host-directed therapy (HDT) options.